We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer, J&J Initiate Phase III Studies of Xarelto in CHF, Afib, Other Indications
The item has been added to your shopping cart.
Bayer, J&J Initiate Phase III Studies of Xarelto in CHF, Afib, Other Indications
March 8, 2013
Bayer and J&J subsidiary Janssen have started five new clinical trials of oral anticoagulant Xarelto, including studies in chronic heart failure (CHF) and nonvalvular atrial fibrillation (NAF).